89bio Overview
- Year Founded
-
2018

- Status
-
Public
- Employees
-
93

- Stock Symbol
-
ETNB

- Share Price
-
$10.07
- (As of Friday Closing)
89bio General Information
Description
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Contact Information
Website
www.89bio.comCorporate Office
- 655 Montgomery Street
- Suite 1500
- San Francisco, CA 94111
- United States
Corporate Office
- 655 Montgomery Street
- Suite 1500
- San Francisco, CA 94111
- United States
89bio Stock Performance
As of 20-Jun-2025, 89bio’s stock price is $10.07. Its current market cap is $1.47B with 146M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$10.07 | $10.00 | $4.16 - $11.84 | $1.47B | 146M | 2.23M | -$3.38 |
89bio Financials Summary
As of 31-Mar-2025, 89bio has a trailing 12-month revenue of null.
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
---|---|---|---|---|
EV | 658,899 | 533,287 | 617,674 | 419,097 |
Revenue | 0 | 0 | 0 | 0 |
EBITDA | (403,249) | (384,618) | (151,154) | (102,184) |
Net Income | (386,673) | (367,079) | (142,189) | (102,026) |
Total Assets | 685,031 | 478,685 | 596,269 | 196,824 |
Total Debt | 37,579 | 37,549 | 27,108 | 20,546 |
89bio Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
89bio Comparisons
Industry
Financing
Details
89bio Competitors (29)
One of 89bio’s 29 competitors is Akero Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Akero Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
Astria Therapeutics | Formerly VC-backed | Boston, MA | ||||
Altimmune | Corporate Backed or Acquired | Gaithersburg, MD | ||||
Galectin Therapeutics | Corporation | Norcross, GA | ||||
aTyr Pharma | Formerly VC-backed | San Diego, CA |
89bio Patents
89bio Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2023329349-A1 | Methods of treatment of nash using mutant fgf-21 peptide conjugates | Pending | 24-Aug-2022 | ||
US-20230414768-A1 | Compositions and methods of treatment for severe hypertriglyceridemia | Active | 24-Jun-2022 | ||
US-12036284-B2 | Compositions and methods of treatment for severe hypertriglyceridemia | Active | 24-Jun-2022 | ||
AU-2023287799-A1 | Compositions and methods of treatment for severe hypertriglyceridemia | Pending | 24-Jun-2022 | ||
EP-4543479-A1 | Compositions and methods of treatment for severe hypertriglyceridemia | Pending | 24-Jun-2022 | A61K47/549 |
89bio Signals
89bio ESG
Risk Overview
Risk Rating
Updated April, 26, 2025
38.77 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,673
Rank
Percentile

Pharmaceuticals
Industry
of 844
Rank
Percentile

Pharmaceuticals
Subindustry
of 419
Rank
Percentile

89bio FAQs
-
When was 89bio founded?
89bio was founded in 2018.
-
Where is 89bio headquartered?
89bio is headquartered in San Francisco, CA.
-
What is the size of 89bio?
89bio has 93 total employees.
-
What industry is 89bio in?
89bio’s primary industry is Drug Discovery.
-
Is 89bio a private or public company?
89bio is a Public company.
-
What is 89bio’s stock symbol?
The ticker symbol for 89bio is ETNB.
-
What is the current stock price of 89bio?
As of 20-Jun-2025 the stock price of 89bio is $10.07.
-
What is the current market cap of 89bio?
The current market capitalization of 89bio is $1.47B.
-
Who are 89bio’s competitors?
Akero Therapeutics, Astria Therapeutics, Altimmune, Galectin Therapeutics, and aTyr Pharma are some of the 29 competitors of 89bio.
-
What is 89bio’s annual earnings per share (EPS)?
89bio’s EPS for 12 months was -$3.38.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »